Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Integrated Bioanalysis
Recent Advances in Top-Down Proteomics for Single-Cell Research
4.2.2.1 Evolution of CZE–MS for SC-TDP The maturation of CZE–MS has enabled the analysis of proteoforms from limited biological samples, culminating in workflows capable of profiling individual mammalian cells (Zhao et al. 2024a, 2025a, 2025b). These capabilities are the result of a finely tuned integration of capillary surface chemistry, background electrolyte (BGE) composition, interface designs, and sample loading strategies.
Reference‐free thio‐succinimide isomerization characterization by electron‐activated dissociation
1 INTRODUCTION Thiol-maleimide conjugation is a highly popular reaction due to its specificity, selectivity, and fast kinetics.1 In recent decades, this reaction has been used in various fields, including biomolecule labelling2 and synthesis of novel polymeric materials.3 One of the most important applications of the thiol-maleimide reaction is the bioconjugation between the linker-payload and antibody backbone to generate antibody-drug conjugates (ADCs).4, 5 Comparing to well-developed small...
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
What is already known about this subject Mitiperstat is a highly potent myeloperoxidase inhibitor in clinical development for the treatment of patients with heart failure, non-alcoholic steatohepatitis and chronic obstructive pulmonary disease. Patients with these conditions often have comorbid renal impairment. Mitiperstat elimination occurs via multiple metabolic pathways and renal excretion.
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
Proliferation of T-follicular helper (T ) CD4+ T cells is a postulated pathogenic mechanism for T-cell non-Hodgkin lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by T , representing a potential target. MEDI-570 is a monoclonal antibody against ICOS, which eliminates ICOS+ cells in preclinical models. We report the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of MEDI-570 in T-NHL.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Integrated
Contact Integrated, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack